High-dose intravenous immune globulin for stiff-person syndrome - PubMed (original) (raw)
Clinical Trial
. 2001 Dec 27;345(26):1870-6.
doi: 10.1056/NEJMoa01167.
Affiliations
- PMID: 11756577
- DOI: 10.1056/NEJMoa01167
Free article
Clinical Trial
High-dose intravenous immune globulin for stiff-person syndrome
M C Dalakas et al. N Engl J Med. 2001.
Free article
Abstract
Background: Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that is characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutamic acid decarboxylase (GAD65), and a frequent association with autoimmune disorders. Because stiff-person syndrome is most likely immune-mediated, we evaluated the efficacy of intravenous immune globulin.
Methods: We assigned 16 patients who had stiff-person syndrome and anti-GAD65 antibodies, in random order, to receive intravenous immune globulin or placebo for three months, followed by a one-month washout period and then by three months of therapy with the alternative agent. Efficacy was judged by improvements in scores on the distribution-of-stiffness index and heightened-sensitivity scale from base line (month 1) to the second and third month of each treatment phase. Direct and carryover effects of treatment were compared in the two groups.
Results: Among patients who received immune globulin first, stiffness scores decreased significantly (P=0.02) and heightened-sensitivity scores decreased substantially during immune globulin therapy but rebounded during placebo administration. In contrast, the scores in the group that received placebo first remained constant during placebo administration but dropped significantly during immune globulin therapy (P=0.01). When the data were analyzed for a direct and a first-order carryover effect, there was a significant difference in stiffness scores (P=0.01 and P<0.001, respectively) between the immune globulin and placebo groups, and immune globulin therapy had a significant direct treatment effect on sensitivity scores (P=0.03). Eleven patients who received immune globulin became able to walk more easily or without assistance, their frequency of falls decreased, and they were able to perform work-related or household tasks. The duration of the beneficial effects of immune globulin varied from six weeks to one year. Anti-GAD65 antibody titers declined after immune globulin therapy but not after placebo administration.
Conclusions: Intravenous immune globulin is a well-tolerated and effective, albeit costly, therapy for patients with stiff-person syndrome and anti-GAD65 antibodies.
Comment in
- High-dose intravenous immune globulin for stiff-person syndrome.
Sudo K, Tajima Y, Matsumoto A. Sudo K, et al. N Engl J Med. 2002 May 30;346(22):1747-8; author reply 1747-8. doi: 10.1056/NEJM200205303462214. N Engl J Med. 2002. PMID: 12037158 No abstract available. - High-dose intravenous immune globulin for stiff-person syndrome.
Solaro C. Solaro C. N Engl J Med. 2002 May 30;346(22):1747-8; author reply 1747-8. N Engl J Med. 2002. PMID: 12041528 No abstract available.
Similar articles
- High-dose intravenous immune globulin for stiff-person syndrome.
Solaro C. Solaro C. N Engl J Med. 2002 May 30;346(22):1747-8; author reply 1747-8. N Engl J Med. 2002. PMID: 12041528 No abstract available. - The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
Dalakas MC. Dalakas MC. J Neurol. 2005 May;252 Suppl 1:I19-25. doi: 10.1007/s00415-005-1105-4. J Neurol. 2005. PMID: 15959668 Clinical Trial. - [Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy].
Shiraishi H, Motomura M, Iwanaga H, Tsujino A, Nishiura Y, Shirabe S, Nakamura T, Yoshimura T. Shiraishi H, et al. Rinsho Shinkeigaku. 2002 Aug;42(8):766-70. Rinsho Shinkeigaku. 2002. PMID: 12701225 Review. Japanese. - Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome.
Espay AJ, Chen R. Espay AJ, et al. Muscle Nerve. 2006 Dec;34(6):677-90. doi: 10.1002/mus.20653. Muscle Nerve. 2006. PMID: 16969837 Review.
Cited by
- Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
Lünemann JD, Nimmerjahn F, Dalakas MC. Lünemann JD, et al. Nat Rev Neurol. 2015 Feb;11(2):80-9. doi: 10.1038/nrneurol.2014.253. Epub 2015 Jan 6. Nat Rev Neurol. 2015. PMID: 25561275 Review. - Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias.
Mitoma H, Honnorat J, Yamaguchi K, Manto M. Mitoma H, et al. Int J Mol Sci. 2020 Jul 13;21(14):4936. doi: 10.3390/ijms21144936. Int J Mol Sci. 2020. PMID: 32668612 Free PMC article. Review. - [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].
Stangel M, Gold R. Stangel M, et al. Nervenarzt. 2004 Aug;75(8):801-15. doi: 10.1007/s00115-004-1733-4. Nervenarzt. 2004. PMID: 15224177 Review. German. - IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.
Dalakas MC. Dalakas MC. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 29;9(1):e1116. doi: 10.1212/NXI.0000000000001116. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34845096 Free PMC article. Review. - Movement disorders in paraneoplastic and autoimmune disease.
Panzer J, Dalmau J. Panzer J, et al. Curr Opin Neurol. 2011 Aug;24(4):346-53. doi: 10.1097/WCO.0b013e328347b307. Curr Opin Neurol. 2011. PMID: 21577108 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources